We are live on ! Find out more
CS

Candriam SCA Portfolio holdings

AUM $19.3B
1-Year Est. Return 39.18%
This Fund
S&P 500
This Quarter Est. Return
+1.91%
1 Year Est. Return
+39.18%
3 Year Est. Return
+109.85%
5 Year Est. Return
+149.31%
10 Year Est. Return
+617.16%
AUM
$14.7B
AUM Growth
+$101M
Cap. Flow
+$158M
Cap. Flow %
1.07%
Top 10 Hldgs %
22.11%
Holding
946
New
64
Increased
332
Reduced
304
Closed
69

Top Buys

Rank Stock Value
1
JNJ icon
Johnson & Johnson
JNJ
+$57.5M
2
AZN icon
AstraZeneca
AZN
+$44.9M
3
ADSK icon
Autodesk
ADSK
+$43.5M
4
MELI icon
Mercado Libre
MELI
+$40.7M
5
AMGN icon
Amgen
AMGN
+$33.6M

Top Sells

Rank Stock Value
1
ALXN
Alexion Pharmaceuticals
ALXN
+$92.5M
2
REGN icon
Regeneron Pharmaceuticals
REGN
+$88M
3
BABA icon
Alibaba
BABA
+$73.8M
4
MRK icon
Merck
MRK
+$49.8M
5
MXIM
Maxim Integrated Products
MXIM
+$48.5M

Sector Composition

Rank Sector Weight
1 Healthcare 32.09%
2 Technology 24.53%
3 Financials 9.08%
4 Communication Services 8.24%
5 Consumer Discretionary 7.84%
Name Market Value Portfolio Weight Shares or Principal Change
in Stake 		Capital Flow
IBM icon
201
IBM
IBM
$204B
$16.4M 0.11%
123,843
+3,680
+3% +$492K
NUE icon
202
Nucor
NUE
$56.4B
$16.4M 0.11%
166,305
+142,779
+607% +$15.2M
COGT icon
203
Cogent Biosciences
COGT
$6.91B
$16.2M 0.11%
1,927,249
+16,529
+0.9% +$127K
CBRE icon
204
CBRE Group
CBRE
$42.1B
$16.1M 0.11%
165,773
-153,591
-48% -$14.3M
SYF icon
205
Synchrony
SYF
$24.5B
$15.9M 0.11%
325,850
-220,592
-40% -$10.7M
BDX icon
206
Becton Dickinson
BDX
$43.8B
$15.8M 0.11%
65,718
– –
GH icon
207
Guardant Health
GH
$19.3B
$15.5M 0.11%
124,372
+26,676
+27% +$3.17M
REPL icon
208
Replimune Group
REPL
$724M
$15.5M 0.11%
522,141
+36,153
+7% +$1.17M
MU icon
209
Micron Technology
MU
$1.02T
$15.4M 0.1%
216,916
+143,596
+196% +$10.8M
CEVA icon
210
CEVA Inc
CEVA
$980M
$15.3M 0.1%
359,669
-1,200
-0.3% -$54.4K
MAN icon
211
ManpowerGroup
MAN
$2.5B
$15.3M 0.1%
141,268
+63,546
+82% +$7.41M
ENB icon
212
Enbridge
ENB
$121B
$15.2M 0.1%
382,182
+335,491
+719% +$13.2M
ATH
213
DELISTED
Athene Holding Ltd. Class A Common Shares
ATH
$15.1M 0.1%
219,060
– –
ARGX icon
214
argenx
ARGX
$55.6B
$15M 0.1%
49,526
– –
DOCU
215
DocuSign
DOCU
$10.1B
$14.9M 0.1%
57,759
-5,255
-8% -$1.51M
FATE icon
216
Fate Therapeutics
FATE
$283M
$14.9M 0.1%
250,737
– –
NSC icon
217
Norfolk Southern
NSC
$77.1B
$14.7M 0.1%
61,490
-365
-0.6% -$93.6K
LH icon
218
Labcorp
LH
$24.7B
$14.5M 0.1%
60,173
+7,624
+15% +$1.92M
IMGN
219
DELISTED
Immunogen Inc
IMGN
$14.5M 0.1%
2,562,935
+101,476
+4% +$586K
CLDR
220
DELISTED
Cloudera, Inc.
CLDR
$14.5M 0.1%
909,868
+136,094
+18% +$2.16M
WFC icon
221
Wells Fargo
WFC
$264B
$14.2M 0.1%
306,059
+71,813
+31% +$3.32M
ITOS
222
DELISTED
iTeos Therapeutics
ITOS
$14.2M 0.1%
525,244
+20,354
+4% +$532K
DD icon
223
DuPont de Nemours
DD
$18.9B
$14M 0.1%
163,816
+1,882
+1% +$174K
ZNTL icon
224
Zentalis Pharmaceuticals
ZNTL
$321M
$13.9M 0.09%
208,526
– –
NEM icon
225
Newmont
NEM
$98.5B
$13.9M 0.09%
255,800
+130,403
+104% +$7.69M
7 8
9
10 11

Similar funds

PCM
Pentwater Capital Management Naples, Florida $19.3B AUM 58.13% 1-Year Est. Return
A
AustralianSuper Melbourne, Australia $19.2B AUM 31.95% 1-Year Est. Return
MGP
M&G plc London, United Kingdom $19.4B AUM 16.7% 1-Year Est. Return
LF
Lansforsakringar Fondforvaltning Stockholm, Sweden $19.1B AUM 26.9% 1-Year Est. Return
Select Equity Group
Select Equity Group New York $19.5B AUM 17.33% 1-Year Est. Return
SOMRS
State of Michigan Retirement System Lansing, Michigan $18.9B AUM 27.96% 1-Year Est. Return
BPA
Beacon Pointe Advisors Newport Beach, California $18.9B AUM 18.9% 1-Year Est. Return
MIM
MetLife Investment Management Whippany, New Jersey $19.6B AUM 32.64% 1-Year Est. Return

Candriam SCA's Q3 2021 Portfolio in Review

As of Q3 2021, Candriam SCA held 946 positions worth $14.7B, up 0.69% from $14.6B the previous quarter. Its ten largest holdings account for 22% of the portfolio.

Candriam SCA's Q3 2021 filing shows 64 new, 332 increased, 304 reduced and 69 closed positions. Its largest new stake was FIVE9: 86,075 shares worth $13.7M. The largest sale was Alexion Pharmaceuticals, an estimated $92.5M.

By sector, the portfolio is most concentrated in Healthcare at 32% of assets, down from 33% a quarter earlier, followed by Technology and Financials.

  • Candriam SCA's largest Q3 2021 buy was FIVE9: 86,075 shares worth $13.7M.
  • Candriam SCA added most to Johnson & Johnson in Q3 2021, an estimated $57.5M increase.
  • Candriam SCA's biggest Q3 2021 reduction was Regeneron Pharmaceuticals, cutting an estimated $88M.
  • Candriam SCA fully exited Alexion Pharmaceuticals in Q3 2021, selling an estimated $92.5M.
  • Candriam SCA's ten largest holdings make up 22% of its $14.7B portfolio in Q3 2021.
  • Candriam SCA opened 64 new positions and closed 69 in Q3 2021.
  • Candriam SCA's portfolio value rose 0.69% quarter-over-quarter to $14.7B.

Based on Candriam SCA's 13F filing for Q3 2021, filed 9 Nov 2021.